Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neurodevelopmental Outcome After Standard Dose Sevoflurane Versus Low-dose Sevoflurane/Dexmedetomidine/Remifentanil Anaesthesia in Young Children- The TREX Trial

NCT03089905 is registered in ClinicalTrials.gov with Murdoch Childrens Research Institute as lead sponsor.

NCT NCT03089905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03089905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neurodevelopmental Outcome After Standard Dose Sevoflurane Versus Low-dose Sevoflurane/Dexmedetomidine/Remifentanil Anaesthesia in Young Children- The TREX Trial
Lead sponsor
Murdoch Childrens Research Institute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 10, 2017
Completion date
October 31, 2026
Enrollment
450 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

anesthesia, child development, neurotoxicity